European biotechnology company Valneva SE ("Valneva") and UK company BliNK Therapeutics Ltd ("BliNK Therapeutics") announced today the closing of the transaction creating BliNK Biomedical SAS, a private company specialised in the discovery of innovative monoclonal antibodies.
The new company is owned by Valneva, Kurma Biofund I (founding investor of BliNK Therapeutics), funds managed by Idinvest Partners, Cancer Research Technology (CRT) and BliNK Therapeutics’ founders.
BliNK Therapeutics’ technology has been developed by Facundo Batista, Head of the Lymphocyte Interaction Laboratory at Cancer Research UK's London Research Institute.
Cancer Research Technology Ltd (CRT), the specialist oncology development and commercialisation company, has today announced the opening of a drug discovery laboratory in Cambridge, adding to Cancer Research UK’s strong presence in the region.
Suil Vision launches to develop virtual reality software that enables immersive, multi-dimensional data analysis for almost any type of biological data.
Amplia Therapeutics Limited announces that it is initiating a Phase 2b study of narmafotinib in pancreatic cancer exploring a new dosing regimen.
